Search Results

Microbot Medical Inc. announces that it has received the U.S. Food and Drug Administration’s approval to proceed with its pivotal human clinical trial as part of its Investigational Device Exemption application for its LIBERTY® Endovascular Robotic Surgical System.

Microbot Medical Inc. announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Microbot Medical Inc., developer of the innovative LIBERTY® Endovascular Robotic Surgical System, reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System’s technical capabilities and outlines potential future applications in a range of endovascular interventions.

Microbot Medical Inc. announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,566,669 shares of the Company’s common stock at a purchase price of $1.50 per share of common stock.

Microbot Medical Inc. announces that Brigham and Women’s Hospital, a leading academic medical center located in Boston, Massachusetts, will participate as a clinical trial site for the pivotal human clinical trial as part of its Investigational Device Exemption application for its LIBERTY® Endovascular Robotic Surgical System.

Microbot Medical Inc., developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption application with the US Food and Drug Administration.